IRESite record type: plasmid_with_promoter_and_putative_IRES_translationally_characterized
The shape of the nucleic acid molecule translated: linear
The quality of the mRNA/+RNA sequence: end-to-end_full-length_mRNA
The mRNA/+RNA description:
Bicistronic RNA encoding B2 and NS´proteins as the first and the second cistron, respectively, with defective
CSFV IRES inserted between them. Putative T7 promoter-derived transcript transcribed either in vitro or
in vivo in BHK-21 cells infected by recombinant vaccinia virus vTF7-3 containing pXLCSFV1-372.NS.
The mRNA/+RNA sequence represented in the +DNA notation:
Credibility of mRNA sequence: end-to-end_sequence_reverse_engineered_and_should_match_experiment
The name of the promoter used to express this mRNA: T7
Description of the plasmid (facultative for promoter-less plasmid records): pXLCSFV1-373.NS is a derivative of pXL10S. CSFV IRES corresponding to 1-373 bp of viral genomic RNA has been
inserted between the two cistrons using SalI and SnaBI enzymes. The pXLJ0S contains T7 and SP6 promoter sites
and is typically used in in vitro transcription/translation assays. Bicistronic RNA, which contains B2 and NS
cistrons (GI:214094, GI:21693177), is transcribed by T7 polymerase after vector linearization by EcoRI.
The in vivo produced transcripts are heterogeneous (due to any of promoter?/splicing?/cleavage?/breakage?): not tested
The in vivo produced heterogeneous transcripts occur due to alternative splicing: not tested
A promoter reported in cDNA corresponding to IRES sequence: not tested
The abbreviated name of the donor gene or virus from which this IRES was excised and inserted into the plasmid: CSFV
The description of the protein encoded in this ORF: Truncated form of influenza NS1 protein which is N-terminally fused with 3 amino acids
The translational frameshift (ribosome slippage) involved: 0
The ribosome read-through involved: no
The alternative forms of this protein occur by the alternative initiation of translation: no
The ORF absolute position (the base range includes START and STOP codons or their equivalents): 1766-2446
Remarks:
IRESite notes about verification of plasmid sequence:
The sequence of pXLCSFV1-373.NS (pXLJ0S respectively) was derived from the pXLJCon sequence which has been
experimentally determined by IRESite curators (please see the IRESite entry 329). The sequence of pXLJ0S
differs from pXLJCon in a creation of SnaBI restriction site at position 4202 of plasmid sequence. A mutation
in vector backbone at position 2808 is indicated in pXLCSFV1-373.NS .gb file provided by IRESite. This
mutation has been detected by sequencing of pXLJCon, thus it is not clear if it is present in pXLJ0S series as
well.